SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-23-017722 from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)

Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 9, 2023 · CIK: 0001671502 · Accession: 0001104659-23-017722

AI Filing Summary & Sentiment

File numbers found in text: 333-269543

Date
February 9, 2023
Author
Not clearly detected
Form
CORRESP
Company
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)

Letter

Quoin Pharmaceuticals Ltd.

42127 Pleasant Forest Court

Ashburn, VA 20148-7349

February 9, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

RE: Quoin Pharmaceuticals Ltd.

Registration Statement on Form S-1

Registration No. 333-269543

Ladies and Gentlemen:

Quoin Pharmaceuticals Ltd. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will become effective at 4:00 p.m.., Eastern Time, on Friday, February 10, 2023, or as soon thereafter as practicable.

[Signature Page Follows]

Very truly yours,
QUOIN PHARMACEUTICALS LTD.

Show Raw Text
CORRESP
1
filename1.htm

Quoin Pharmaceuticals Ltd.

42127 Pleasant Forest Court

Ashburn, VA 20148-7349

February 9, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 RE: Quoin Pharmaceuticals Ltd.

Registration Statement on
Form S-1

Registration
No. 333-269543

Ladies and Gentlemen:

Quoin Pharmaceuticals Ltd.
(the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration
of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will
become effective at 4:00 p.m.., Eastern Time, on Friday, February 10, 2023, or as soon thereafter as practicable.

[Signature Page Follows]

    Very truly yours,

    QUOIN PHARMACEUTICALS LTD.

    By:
    /s/ Dr. Michael Myers

    Name: Dr. Michael Myers

    Title: Chief Executive Officer